Prasugrel

Drug Profile

Prasugrel

Alternative Names: CS-747; CS-747S; Effient; Efient; LY 640315; R-138727; R-99224

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company; Ube Industries
  • Developer Daiichi Sankyo Company; Eli Lilly; Ube Industries
  • Class Antiplatelets; Antithrombotics; Cyclopropanes; Fluorobenzenes; Small molecules; Thienopyridines
  • Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes
  • Phase III Sickle cell anaemia; Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Sickle-cell-anaemia in United Kingdom (PO, Tablet)
  • 21 Oct 2016 Daiichi Sankyo completes a phase-III clinical trial in Stroke in Japan (PO) (JapicCTI-111582)
  • 25 May 2016 Single dose 20mg prasugrel available for Acute coronary syndromes with PCI in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top